Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,261 to 4,280 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach | 383 of 753 399 of 747 | -2.6 points -7.6 to 2.5 | 1,500 | NCT02100228 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) |
| FFR Guided PCI vs CABG: Number of Participants Experiencing BARC Type 3-5 Bleeding | 12 of 757 28 of 743 | -2.2 points -3.9 to -0.5 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Death, MI, or Stroke at 5 Years | 119 of 757 101 of 743 | 2.1 points -1.5 to 5.7 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Number of Participants Experiencing Death, MI, or Stroke | 55 of 757 39 of 743 | 2.0 points -0.5 to 4.5 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Number of Participants Requiring Rehospitalization Within 30 Days | 42 of 757 76 of 743 | -4.7 points -7.5 to -2.0 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: MACCE | 188 of 757 131 of 743 | 7.2 points 3.1 to 11.3 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Key Secondary Outcome: Composite of Death From Any Cause, Myocardial Infarction, or Stroke | 91 of 757 68 of 743 | 2.9 points -0.3 to 6.0 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Number of Participants Experiencing Atrial Fibrillation or Clinically Significant Arrhythmia | 18 of 757 105 of 743 | -11.8 points -14.6 to -9.1 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: MACCE | 80 of 757 51 of 743 | 3.7 points 0.8 to 6.6 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: deaths from any cause | 31 of 757 29 of 743 | 0.2 points -1.8 to 2.2 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: serious adverse events | 119 of 757 101 of 743 | 2.1 points -1.5 to 5.7 | 1,500 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| GSK3390107A Group vs Placebo+GSK3390107A Group: Number of Subjects With Unsolicited Adverse Events (AEs) | 123 of 749 119 of 751 | 0.6 points -3.2 to 4.3 | 1,500 | NCT02485301 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults |
| Everolimus vs Placebo: deaths from any cause | 139 of 755 151 of 744 | -1.9 points -5.9 to 2.1 | 1,499 | NCT01120249 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery |
| SCH 697243 vs Placebo: serious adverse events | 14 of 753 9 of 745 | 0.7 points -0.7 to 2.0 | 1,498 | NCT01385371 A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) |
| Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of an Unplanned Readmission Within 30 Days Post-discharge | 58 of 749 41 of 749 | 2.3 points -0.3 to 4.8 | 1,498 | NCT02081846 Hospital to Home Outcomes |
| Home Nurse Visit vs Control: Number of Participants With Any Occurrence of Unplanned Re-hospitalization and/or Any Emergency/Urgent Care Visits Within 30 Days of Hospital Discharge | 133 of 749 105 of 749 | 3.7 points 0.0 to 7.4 | 1,498 | NCT02081846 Hospital to Home Outcomes |
| Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of 14-day Unplanned Healthcare Utilization | 132 of 749 110 of 749 | 2.9 points -0.8 to 6.7 | 1,498 | NCT02081846 Hospital to Home Outcomes |
| Home Nurse Visit vs Control: Number of Participants With Occurrence(s) of an Emergency Department Visit Within 30 Days Post-discharge | 75 of 749 54 of 749 | 2.8 points -0.0 to 5.7 | 1,498 | NCT02081846 Hospital to Home Outcomes |
| Acute Phase: ZS vs Extended Dosing Phase: ZS: deaths from any cause | 0 of 751 8 of 746 | -1.1 points -2.1 to -0.3 | 1,497 | NCT02163499 Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months |
| Acute Phase: ZS vs Extended Dosing Phase: ZS: serious adverse events | 1 of 751 161 of 746 | -21.4 points -24.5 to -18.6 | 1,497 | NCT02163499 Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months |
Code
curl "https://conductscience.org/api/comparisons/v1?page=214"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=214
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02100228-f1d663f1",
"title": "Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants Who Used Image Guidance Approach",
"summary": "383 of 753 against 399 of 747; risk difference -2.6 points, 95% interval -7.6 to 2.5; NCT02100228, Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",
"record": "/library/comparisons/NCT02100228-f1d663f1",
"nct_id": "NCT02100228",
"kind": "outcome",
"participants": 1500,
"risk_difference": {
"value": -0.025504408070529117,
"lower": -0.07582681851416401,
"upper": 0.025003309981620918
},
"group_1": "383 of 753",
"group_2": "399 of 747",
"difference": "-2.6 points",
"interval": "-7.6 to 2.5",
"trial_title": "Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)"
},
{
"id": "NCT02100722-11c2e907",
"title": "FFR Guided PCI vs CABG: Number of Participants Experiencing BARC Type 3-5 Bleeding",
"summary": "12 of 757 against 28 of 743; risk difference -2.2 points, 95% interval -3.9 to -0.5; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
"record": "/library/comparisons/NCT02100722-11c2e907",
"nct_id": "NCT02100722",
"kind": "outcome",
"participants": 1500,
"risk_difference": {
"value": -0.02183301300913324,
"lower": -0.03942526078675258,
"upper": -0.005473522214226142
},
"group_1": "12 of 757",
"group_2": "28 of 743",
"difference": "-2.2 points",
"interval": "-3.9 to -0.5",
"trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=215",
"request_id": "toeljlPGK5s4dlzc"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant